Safety threat forces Enanta to scrap HBV trials — sending discovery team back to drawing board

Josh Sullivan

A Massachusetts biotech will discontinue the development of its oral drug intended to treat patients suffering from chronic hepatitis B infections, the company said Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Safety threat forces Enanta to scrap HBV trials — sending discovery team back to drawing board

Josh Sullivan

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Safe­ty threat forces Enan­ta to scrap HBV tri­als — send­ing dis­cov­ery team back to draw­ing board

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Safety threat forces Enanta to scrap HBV trials — sending discovery team back to drawing board